70954-01-7Relevant academic research and scientific papers
Synthesis of Urea Derivatives from CO2 and Silylamines
Xu, Maotong,Jupp, Andrew R.,Ong, Maegan S. E.,Burton, Katherine I.,Chitnis, Saurabh S.,Stephan, Douglas W.
, p. 5707 - 5711 (2019/04/16)
A series of thirty-three N,N′-diaryl, dialkyl, and alkyl-aryl ureas have been prepared in pyridine or toluene by reaction of silylamines with CO2. This protocol is shown to provide facile access to 13C-labeled ureas, as well as chiral and macrocyclic ureas. These reactions proceed through initial generation of the corresponding silylcarbamates, which subsequently react with silylamine under thermal conditions to afford the thermodynamically favored urea and disilyl ether.
Synthesis of cyanoformamides from primary amines and carbon dioxide under mild conditions. Synthesis of ceratinamine
Garcia-Egido, Eduardo,Paz, Jairo,Iglesias, Beatriz,Munoz, Luis
experimental part, p. 3991 - 3999 (2009/12/06)
Treatment of primary amines with tetramethylphenylguanidine (PhTMG) and a cyanophosphonate at -10 °C under an atmosphere of carbon dioxide provides cyanoformamides in very high to excellent yields. The reaction proceeds efficiently within a short time. By
Cobalt/rhodium heterobimetallic nanoparticle-catalyzed oxidative carbonylation of amines in the presence of carbon monoxide and molecular oxygen to ureas
Park, Ji Hoon,Yoon, Jae Chun,Chung, Young Keun
supporting information; experimental part, p. 1233 - 1237 (2009/12/07)
An environmentally friendly oxidative carbonylation of aliphatic and aromatic primary amines to ureas has been successfully achieved in the presence of a catalytic amount of cobalt/rhodium heterobimetallic nanoparticles without any promoters. The catalyst system could be reused with only a slight loss of catalytic activity.
BETA-SECRETASE MODULATORS AND METHODS OF USE
-
Page/Page column 203, (2010/11/27)
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
Synthesis and conformational analysis of chiral ureas incorporating N-1-phenylethyl groups. Manifestation ofallylic 1,3-strain
Hernandez-Rodriguez, Marcos,Melgar-Fernandez, Roberto,Juaristi, Eusebio
, p. 792 - 799 (2007/10/03)
The synthesis of novel chiral ureas (R,R)-2, (S,S)-3 and (R)-6 incorporating the α-phenylethyl group is described. Conformational analysis of these ureas, and of previously reported (R,R)-1, was carried out computationally, both at semiempirical (AMI and
Aldol Addition Reaction of Chiral Acetylurea and a Convenient Synthesis of Optically Pure Methyl β-Alkyl-β-hydroxypropionate
Kishikawa, Keiki,Yamamoto, Makoto,Kohmoto, Shigeo,Yamada, Kazutoshi
, p. 787 - 790 (2007/10/02)
The aldol addition reaction of chiral acetylurea with aldehydes diastereoselectively gives β-alkyl-β-hydroxypropionylureas (3 and 4) and the methanolysis of the adducts 3 and 4, separated perfectly by conventional column chromatography on silica gel, give
